GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion.

(Alliance News) - GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to buy steatotic liver disease medication efimosfermin alfa.

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

GSK announced on Wednesday that it has entered into an agreement with Boston Pharmaceuticals to acquire its lead asset ...

Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment optionsPhase II data show ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works ...

Researchers at the University of Oklahoma report a hormone, FGF21, may reverse fatty liver disease by signaling the brain.

Altimmune's Q1 2025 earnings call highlights breakthroughs in NASH treatments, robust financials with a new $100M credit facility, and imminent Phase ...

Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ETCompany ParticipantsLee Roth - President, Burns McClellan, ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...